-
NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
Monday, April 9, 2018 - 2:24pm | 355NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat. The Analyst Baird Equity Research's Michael Ulz...
-
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
Monday, April 9, 2018 - 10:29am | 422NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...
-
Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial
Friday, April 6, 2018 - 8:50am | 372Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...
-
The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment
Monday, October 10, 2016 - 12:08pm | 394BMO Capital’s M. Ian Somaiya expects higher probability of success for Incyte Corporation (NASDAQ: INCY)'s epacadostat+Keytruda trials in melanoma, given the PFS strength in the updated Phase I data presented at the meeting of the European Society for Medical Oncology. Somaiya maintains an...